Multicenter observational program for evaluation of the effectiveness of the recognan (citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology

Машин, В В; Belova, L. A.; Bakhtogarimov, Ildar; Bergelson, T. M.; Sharafutdinova, R

doi:10.17116/jnevro20171178139-43

Cited by 20 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, citicoline caused no significant effect on both males and females regarding the activation of psychomotor speed and cognitive functions following ischemic stroke (Alvarez-Sabín et al, 2016;Mashin, Belova, Bakhtogarimov, Bergelson, & Sharafutdinova, 2017). This insignificant effect of citicoline on both genders might be related to the insignificant differences in male and female cognitive functions.…”

Section: Discussionmentioning

confidence: 92%

Citicoline Improves Human Vigilance and Visual Working Memory: The Role of Neuronal Activation and Oxidative Stress

Al-Kuraishy

Al-Gareeb

2020

Basic Clin. Neurosci. J.

View full text Add to dashboard Cite

Introduction: Psychomotor performance task is used to assess the arousal and cognitive functions of the central nervous system. Alternatively, human visual working memory reflects the capability of the individual’s short-term memory. Psycho-mental stimuli are linked to the stimulation of Malondialdehyde (MDA) formations. Citicoline is a nootropic nucleotide agent with a favorable effect on the augmentation of human memory and cognitive function. Thus, the purpose of this study was to determine the effect of citicoline on human vigilance, visual working memory, and oxidative stress using healthy volunteers. Methods: 40 healthy volunteers were enrolled and divided into two groups: group A: 20 volunteers received 500mg/day starch capsule for two weeks and group B: 20 volunteers received 500mg/day citicoline capsule for two weeks. Human vigilance, visual working memory, and oxidative stress markers of each volunteer were assessed before and after citicoline and placebo intake. The obtained data were analyzed by SPSS regarding P<0.05 as statistically significant. Results: Placebo had no significant effect on human vigilance and visual working memory after two weeks of therapy (P>0.05), whereas citicoline improved most variables of psychomotor performances and working memory (P<0.01). Placebo significantly increased serum MDA levels from 19.44±2.11 to 29.66±3.28 nmol/mL (P=0.0001), while citicoline significantly decreased MDA serum levels from 19.11±2.66 to 15.63±1.33 nmol/mL (P=0.0001). Conclusion: Citicoline improves human psychomotor vigilance, arousal, and visual working memory with significant amelioration of oxidative stress compared with placebo.

show abstract

Section: Discussionmentioning

confidence: 92%

Citicoline Improves Human Vigilance and Visual Working Memory: The Role of Neuronal Activation and Oxidative Stress

Al-Kuraishy

Al-Gareeb

2020

Basic Clin. Neurosci. J.

View full text Add to dashboard Cite

show abstract

“…Some positive effects in patients with chronic cerebrovascular disease have also been demonstrated [243][244][245][246][247][248][249][250][251][252][253][254][255][256][257][258][259][260][261]. However, in patients with vascular dementia according to current diagnostic criteria, Cohen et al [262] were not able to show any beneficial effect of citicoline in their pilot study.…”

Section: Experimental Datamentioning

confidence: 99%

Citicoline in the Treatment of Cognitive Impairment

Secades¹

2019

J Neurol Exp Neurosci

View full text Add to dashboard Cite

Vascular cognitive impairment is a process which is more frequent in patients with cardiovascular risk factors. The etiology of this kind of impairment could be related to different types of cerebrovascular disorders, given that silent cerebral infarctions or microinfarcts, correlated with small vessel disease, are one of the principal etiologies. Microinfarcts, associated with small vessel diseases, should be considered one of the possible causes of clinical suspicion in patients with cardiovascular risk factors who are asking for help for cognitive complaints. Among the proposed treatments for cognitive impairment there is citicoline. This is an updated review of the possible use of citicoline in the treatment of cognitive impairment.

show abstract

“…Kovalenko and Lytvyn [ 719 ] showed that citicoline treatment in patients with hypertensive dyscirculatory encephalopathy and concomitant hypothyroidism significantly improves the performance of brain electrogenesis. Mashin et al [ 720 ] concluded that treatment with citicoline in patients with chronic cerebrovascular pathologies improved cognitive function, memory and visuo-spatial coordination, and decreased depression severity. Chutko et al [ 721 ] indicated that the use of citicoline in the treatment of patients with somatoform dysfunction of the autonomic nervous system was highly effective (improvements occurred in 67.4% of patients), including cognitive function.…”

Section: Clinical Experiencementioning

confidence: 99%

“…Kovalenko y Lytvyn [ 719 ] demostraron que el tratamiento con citicolina en pacientes con encefalopatía discirculatoria hipertensiva e hipotiroidismo concomitante mejora significativamente el rendimiento de la electrogenia cerebral. Mashin et al [ 720 ] concluyeron que el tratamiento con citicolina en pacientes con patologías cerebrovasculares crónicas mejoraba la función cognitiva, la memoria y la coordinación visuoespacial, y disminuía la gravedad de la depresión. Chutko et al [ 721 ] indicaron que el uso de citicolina en el tratamiento de pacientes con disfunción somatomorfa del sistema nervioso autónomo fue altamente efectivo (se produjeron mejoras en el 67,4% de los pacientes), incluida la función cognitiva.…”

Section: Experiencia Clínicaunclassified

Citicolina: revisión farmacológica y clínica, actualización 2022

Ruiz¹,

Gareri²

2022

RevNeurol

View full text Add to dashboard Cite

Resumen Esta revisión se basa en la publicada en 2016 –Secades JJ. Citicolina: revisión farmacológica y clínica, actualización 2016. Rev Neurol 2016; 63 (Supl 3): S1-S73–, e incorpora 176 nuevas referencias aparecidas desde entonces, con toda la información disponible para facilitar el acceso a toda la información en un único documento. La revisión se centra en las principales indicaciones del fármaco, como los accidentes cerebrovasculares agudos y sus secuelas, incluyendo el deterioro cognitivo, y los traumatismos craneoencefálicos y sus secuelas. Se recogen los principales aspectos experimentales y clínicos en estas indicaciones.

show abstract

Multicenter observational program for evaluation of the effectiveness of the recognan (citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology

Abstract: Recognan reduced cognitive dysfunction and disturbances of visual/spatial coordinationas well as had a positive effect on the emotional sphere decreasing the level of depression.

Cited by 20 publications

References 9 publications

Citicoline Improves Human Vigilance and Visual Working Memory: The Role of Neuronal Activation and Oxidative Stress

Citicoline Improves Human Vigilance and Visual Working Memory: The Role of Neuronal Activation and Oxidative Stress

Citicoline in the Treatment of Cognitive Impairment

Citicolina: revisión farmacológica y clínica, actualización 2022

Contact Info

Product

Resources

About